An unbiased multidisciplinary approach to identify novel targets in major depressive disorder

An interdisciplinary review synthesizes experimental and mechanistic evidence linking neuroinflammation, tryptophan metabolism, and the pathophysiology of major depressive disorder. Published in Mo Med (Jan–Feb 2024) with PMID 38404431 and PMCID PMC10887465, the article examines competing metabolic fates of tryptophan and emphasizes how shifts within these pathways contribute to oxidative stress, excitotoxicity, and impaired synaptic plasticity. The authors describe how inflammatory signaling activates enzymes such as tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO1 and IDO2), driving tryptophan toward the kynurenine pathway. Within this pathway, enzymatic decisions determine whether neuroprotective kynurenic acid (KYNA) or neurotoxic metabolites such as 3-hydroxykynurenine, 3-hydroxyanthranilic acid (3-HAA), and quinolinic acid (QUIN) predominate. The review highlights that increased synthesis of QUIN occurs at the expense of KYNA, creating a biochemical shift that promotes NMDA receptor activation, calcium and sodium influx, excitotoxic neuronal injury, and apoptotic processes. 3-HAA and QUIN are identified as contributors to hydroxyl radical production and oxidative stress, reinforcing a cycle of neuroinflammation and neurotoxicity implicated in depression and neurodegenerative conditions.

The article uses schematic figures to illustrate the kynurenine pathway and NMDA receptor interactions, clarifying how cytokines such as IL-1β, TNF-α, and IFN-γ influence enzyme activity and downstream metabolite balance. The authors contextualize these molecular mechanisms within broader depression research, referencing literature that spans metabolic, inflammatory, and clinical economic perspectives. Throughout, the review underscores the importance of metabolic equilibrium between neuroprotective and neurotoxic kynurenine pathway products for maintaining synaptic plasticity and preventing mood disorder progression.

Importantly, the authors also consider nutritional modulation as a potential protective strategy. They note that adequate protein intake ensuring sufficient tryptophan availability, combined with dietary antioxidants and flavonoids, may help preserve favorable metabolic balance and mitigate risk for major depressive and neurodegenerative disorders. While the review is descriptive and integrative rather than interventional, it points to dietary and metabolic factors that could be considered in multidisciplinary approaches to identify novel therapeutic targets.

As a review article authored by researchers and trainees at Kansas City University, including Asma Zaidi, the work is positioned as a synthesis of current understanding rather than original experimental data. The manuscript reports no conflicts of interest and states that artificial intelligence was not used in the study, research, preparation, or writing of the manuscript. By mapping the biochemical pathways connecting inflammation, tryptophan metabolism, and neurotransmitter receptor dynamics, Zaidi and colleagues provide a concise yet comprehensive resource for investigators seeking targetable nodes—such as the enzymes that divert kynurenine metabolism and the receptors affected by downstream metabolites—within the complex network linking neurochemistry and major depressive disorder.